Pasithea Therapeutics (KTTA) Accounts Payables (2020 - 2026)

Pasithea Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 12.34% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 12.34% YoY), while the FY2025 annual figure was $1.1 million, up 1.0% from the prior year.
• Accounts Payables came in at $1.5 million for Q1 2026 at Pasithea Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.6 million in Q4 2023 to a low of $141790.0 in Q1 2023.
• A 5-year average of $1.4 million and a median of $1.3 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables tumbled 67.31% in 2023 and surged 1616.62% in 2024, its largest moves.
• Pasithea Therapeutics' Accounts Payables stood at $1.5 million in 2022, then surged by 72.29% to $2.6 million in 2023, then sank by 56.12% to $1.1 million in 2024, then climbed by 1.0% to $1.1 million in 2025, then soared by 31.68% to $1.5 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $1.5 million, $1.1 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison